Efficacy of second line (2L) treatment with Tivozanib (Tivo) as monotherapy or with Nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the Phase 3 TiNivo-2 study
Tag: Tivozanib
Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)
Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)
Patient-Reported Outcomes (PROs) for Tivozanib + Nivolumab (Tivo-Nivo) vs. Tivozanib (Tivo) Monotherapy in Patients With Renal Cell Carcinoma (RCC) Following an Immune Checkpoint Inhibitor (ICI): Results of the Phase 3 TiNivo-2 Study
Patient-Reported Outcomes (PROs) for Tivozanib + Nivolumab (Tivo-Nivo) vs. Tivozanib (Tivo) Monotherapy in Patients With Renal Cell Carcinoma (RCC) Following an Immune Checkpoint Inhibitor (ICI): Results of the Phase 3 TiNivo-2 Study
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
Authors: Miguel Zugman, David F. McDermott, Bernard J. Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Brian Rini, Sumanta K. Pal. Click here for link to article.
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
Authors: Jeffrey Thomas Yorio, Aviva G. Asnis-Alibozek, Vijay Kasturi, Thomas E. Hutson. Click here for link to article.
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
Authors: Toni K. Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina-Cerrillo, Benjamin Garmezy, Pedro Barata, Arnab Basu, Maria T. Bourlon, Helen Moon, Raffaele Ratta, Rana R. McKay, Alexander Chehrazi-Raffle, Hans Hammers, Daniel Y. C. Heng, Edgar Braendle, Kathryn E. Beckermann, Bradley A. McGregor, Robert J. Motzer. Click here for link to article.
ESMO 2024: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study
ESMO 2024: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial | The Oncologist | Oxford Academic
Authors: Kathryn E. Beckermann, Aviva G. Asnis-Alibozek, Michael B. Atkins, Bernard Escudier, Thomas E. Hutson, Vijay Kasturi, David F. McDermott, Sumanta K. Pal, Camillo Porta, Brian I. Rini, Elena Verzoni. Click here for link to article.
Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study
Authors: Brian I. Rini, Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott. Request for Reprint of The Lancet Oncology TIVO-3 Manuscript.
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
Authors: Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal. Click here for link to article.